INMB Historical PE Ratio Notes

— INmune Bio (ticker symbol INMB) is a clinical-stage biotechnology company focused on developing therapies targeting innate immunity to treat serious diseases such as Alzheimer's, cancer, & inflammatory conditions. Unlike traditional biopharma firms with large portfolios of marketed products, INmune Bio has historically operated at a pre-revenue or early clinical trial stage, with minimal or negative earnings. This directly impacts historical P/E ratio calculations—since the company frequently posts losses, its P/E ratio is often negative, undefined, or not meaningful over much of its trading history. Investors researching INMB's historical P/E ratio will likely observe inconsistencies or gaps in the data. Such figures should be interpreted cautiously, as they do not reflect mature earnings power but rather the high-risk, high-reward profile typical of biotech firms in R&D phases. The market's valuation of INMB has therefore been driven more by pipeline progress, clinical trial results, partnership announcements, & speculation rather than current earnings, so traditional valuation metrics like P/E may have limited utility until (or if) the company brings products to market & achieves stable profitability.

On this page we presented the INmune Bio Historical PE Ratio information for INmune Bio' stock. The average INMB historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average INMB historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this INMB historical PE result, against the recent PE: when this page was posted on 5/13/2026, the most recent closing price for INMB had been 1.46, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on INMB or any other given stock, valuation analysis for INMB can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate INmune Bio PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for INMB. Thanks for visiting, and the next time you need to research INMB Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.